LuisP

Dark cinematic banner with Kite Pharma logo and Tecartus FDA full approval headline on molecular background

FDA Converts Tecartus to Full Approval in Relapsed Mantle Cell Lymphoma

AI in Regulatory Intelligence /

The FDA granted full approval to Tecartus on April 3 2026 for adult patients with relapsed or refractory mantle cell lymphoma based on ZUMA-2 cohort 3 data showing a 91% response rate in BTK-naive patients. Full approval removes payer friction and expands the eligible patient population but increases pressure on CAR-T manufacturing capacity and treatment centre readiness.

FDA Converts Tecartus to Full Approval in Relapsed Mantle Cell Lymphoma Read More »

Dark cinematic 16:9 banner with electric blue molecular network and teal data compression visual representing AI accelerating every layer of biotech simultaneously

AI Is Compressing Every Layer of Biotech at the Same Time

AI in Clinical Development /

In the week of March 29 to April 5, 2026, four simultaneous signals confirmed that AI is compressing every layer of the biotech value chain at once. Insilico Medicine published Phase IIa results for the first wholly AI-designed drug. NVIDIA expanded BioNeMo for life sciences. Tempus AI reported a 27% improvement in trial patient identification. EvolutionaryScale released ESM Cambrian. The cumulative effect on development timelines and commercial NPV is multiplicative, not additive.

AI Is Compressing Every Layer of Biotech at the Same Time Read More »

Dark cinematic 16:9 banner with electric blue financial data models and teal pipeline valuation accents representing AI-driven biotech asset valuation

AI Biotech Valuation Modeling: Why the rNPV Spreadsheet Is No Longer Enough

AI in Biotech Finance /

Traditional rNPV models are underperforming for AI-discovered biotech assets because their probability of success benchmarks and competitive intelligence inputs do not reflect the speed at which AI pipelines and competitive landscapes change. AI valuation tools add continuous competitive monitoring, AI-calibrated PoS inputs, and rapid scenario generation. This article explains where the leverage points are and how to start.

AI Biotech Valuation Modeling: Why the rNPV Spreadsheet Is No Longer Enough Read More »

Dark cinematic 16:9 banner with electric blue safety signal data visualisation and teal molecular accents representing AI-driven pharmacovigilance

AI Signal Detection in Pharmacovigilance: Find the Safety Signal First

AI in Pharmacovigilance /

AI signal detection tools are cutting ICSR processing time by 40 to 60 percent and enabling continuous literature monitoring that manual processes cannot match. The global PV market reached $8.99 billion in 2025. This article explains how biotech PV teams can deploy AI surveillance tools within GxP compliance requirements and where the firm data boundaries sit.

AI Signal Detection in Pharmacovigilance: Find the Safety Signal First Read More »

Dark cinematic 16:9 banner with electric blue regulatory document grid and teal data accents representing AI-assisted pharma regulatory submissions

AI Regulatory Submission Drafting: From Months to Weeks Without Cutting Corners

AI in Regulatory Intelligence /

AI regulatory submission drafting is cutting variation and NDA dossier preparation time by days per submission. FDA and EMA aligned on joint AI principles in January 2026. This article maps where AI adds value in regulatory workflows, the compliance guardrails that apply, and how teams can build AI drafting capability without creating regulatory risk.

AI Regulatory Submission Drafting: From Months to Weeks Without Cutting Corners Read More »

Dark cinematic 16:9 banner with electric blue price corridor data visualisation and teal accents representing AI-driven pharma pricing strategy

AI Price Corridor Modeling: Stop Leaving Money on the Table at Launch

AI in Market Access and Pricing /

The MFN executive order and IRA have made pharma pricing a dynamic multi-market corridor management challenge. AI price corridor models continuously track IRP linkages, HTA outcomes, and launch sequence implications across markets. This article explains how biotech market access teams can build AI corridor modeling capability using publicly available data.

AI Price Corridor Modeling: Stop Leaving Money on the Table at Launch Read More »

Dark cinematic banner showing a professional at a desk with AI data visualisation and electric blue teal accents representing personal AI productivity

AI Is Not Just a Work Tool. It Is a Personal Competitive Weapon.

AI Governance for Biotech Executives /

Some pharma and biotech professionals are gaining 5 hours a week using personal AI setups at home to prepare for meetings, sharpen decisions, and outpace colleagues. This article explains the generational anxiety driving AI avoidance, why experience is still an advantage when paired with AI, and what a practical personal AI setup looks like for professionals who want to get ahead.

AI Is Not Just a Work Tool. It Is a Personal Competitive Weapon. Read More »

Dark cinematic banner with electric blue data grid and teal accents representing AI governance in a pharma office setting

AI for Pharma Office Workers: The Compliant Path Forward

AI Governance for Biotech Executives /

Pharma and biotech office workers are losing productivity to blanket AI bans while IT offers only one approved tool. This article defines the real data risk boundary, identifies compliant enterprise AI tools including Microsoft 365 Copilot, Veeva AI, and Azure OpenAI, and outlines a four-step path forward for organisations ready to move beyond restriction and into governed AI enablement.

AI for Pharma Office Workers: The Compliant Path Forward Read More »